New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLL-37 vs Teduglutide

LL-37 vs Teduglutide

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
LL-37
Recovery & Repair
Teduglutide
Summary
LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
Half-Life
Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
~2 hours; once-daily dosing due to gut-specific residence
Admin Route
SubQ, Topical, Intranasal
SubQ
Research
Typical Dose
100–300 mcg
0.05 mg/kg/day
Frequency
2–3x per week
Once daily
Key Benefits
  • Broad-spectrum antimicrobial (bacteria, fungi, viruses)
  • Promotes wound healing and angiogenesis
  • Immune system modulation — enhances innate immunity
  • Reduces LPS-mediated endotoxemia
  • Anti-biofilm activity against resistant organisms
  • Promotes tissue regeneration and keratinocyte migration
  • May protect against sepsis
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
Side Effects
  • Injection site redness and irritation
  • Mild inflammatory response at injection site
  • Potential pro-inflammatory at high doses
  • Rare: fever or flu-like symptoms at initiation
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
Stacks With